Northwire Canada EditionWednesday, July 15, 2026
Sign inSubscribe
Northwire
⌕
EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0% EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0%

Healthcare

Page 61
  1. Feb 17, 2026 · 03:05 · BNXT

    BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis

    BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis

    01
  2. Feb 13, 2026 · 15:24 · MDNA

    Medicenna's Dec. 31 cash at $10.6 million

    Medicenna's Dec. 31 cash at $10.6 million

    02
  3. Feb 13, 2026 · 13:27 · HELP

    Cybin's Dec. 31 cash at $195.1-million (U.S.)

    Cybin's Dec. 31 cash at $195.1-million (U.S.)

    03
  4. Feb 13, 2026 · 12:29 · CNVI

    Conavi highlights hybrid IVUS-OCT study results

    Conavi highlights hybrid IVUS-OCT study results

    04
  5. Feb 13, 2026 · 08:09 · MDNA

    Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update

    Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update

    05
  6. Feb 13, 2026 · 07:31 · HELP

    HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

    HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

    06
  7. Feb 13, 2026 · 07:00 · CNVI

    Conavi Medical Highlights Peer-Reviewed Publication Demonstrating Advantages of Hybrid IVUS-OCT Imaging

    Conavi Medical Highlights Peer-Reviewed Publication Demonstrating Advantages of Hybrid IVUS-OCT Imaging

    07
  8. Feb 13, 2026 · 01:36 · 4565

    Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025

    Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025

    08
  9. Feb 12, 2026 · 19:58 · GSD

    Devonian preclinical data support Thykamine

    Devonian preclinical data support Thykamine

    09
  10. Feb 12, 2026 · 19:49 · ONCO

    Onco-Innovations lowers per-unit price of placement

    Onco-Innovations lowers per-unit price of placement

    10
  11. Feb 12, 2026 · 18:15 · APLI

    Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026

    Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026

    11
  12. Feb 12, 2026 · 17:17 · MBX

    Microbix loses $1.16-million in fiscal Q1

    Microbix loses $1.16-million in fiscal Q1

    12
  13. Feb 12, 2026 · 17:14 · KNE

    Kane Biotech revives commercial activity for revyve gel

    Kane Biotech revives commercial activity for revyve gel

    13
  14. Feb 12, 2026 · 12:38 · MSCL

    Satellos says first participant dosed in DMD study

    Satellos says first participant dosed in DMD study

    14
← Newer Older →